Sharon Rosenberg, MD
Pulmonary Disease · Chicago, ILNPI 1437306396
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,100 of the $53,330 with a category attached, or 92.1%. GSK accounts for 98.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $19,176 and has fallen 77.1% since, to $4,383 in 2025. Among pulmonary disease clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $620.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$52K
- AstraZeneca$624
- Verona Pharma, Inc.$97
- Amgen$64
- Merck$43
- Sunovion Pharmaceuticals Inc.$43
- plus $25 from 1 others
Across 24 payments — averaging $6479.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$98K
- Regeneron$58K
What the payments were for
- Speaking & faculty fees$49,10092%
- Travel & lodging$2,8825%
- Food & beverage$1,3483%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 61 | $52,434 |
| AstraZeneca | 13 | $624 |
| Verona Pharma, Inc. | 3 | $97 |
| Amgen | 4 | $64 |
| Merck | 2 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Insmed, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,330 in reported general payments places this provider in the 90th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 446 | $397,782 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 226 | $157,252 |
| Breo ElliptaFluticasone/Vilanterol | 170 | $98,794 |
| NucalaMepolizumab | 24 | $85,974 |
| Dupixent SyringeDupilumab | 21 | $85,649 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 94 | $71,813 |
| Fasenra PenBenralizumab | 11 | $61,772 |
| Spiriva RespimatTiotropium Bromide | 86 | $60,593 |
| Incruse ElliptaUmeclidinium Bromide | 109 | $47,506 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $31,381 |
| SymbicortBudesonide/Formoterol Fumarate | 70 | $27,662 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 69 | $16,898 |
| Arnuity ElliptaFluticasone Furoate | 41 | $15,298 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 368 | $13,823 |
| DuleraMometasone/Formoterol | 21 | $13,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta | $52,434 | $802,6061,016 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $624 | $59,04398 claims |
| MerckDulera | $43 | $13,15221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Chicago
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Manu JainChicago$187K
- Richard WunderinkChicago$178K
- Rade TomicChicago$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.